All In Biotech

Drug Trial Radar · NCT01946204

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,207 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,207

Actual

Start

Oct 14, 2013

Primary completion

May 19, 2017

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Aragon Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • ApalutamideDrug

    240 mg tablets administered by mouth on a continuous once daily dosing regimen

  • PlaceboDrug

    Matched placebo tablets administered by mouth on a continuous once daily dosing regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 43 Months

Locations

379 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Chandler, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Duarte, California

  • Site not named

    Fullerton, California

  • Site not named

    Laguna Woods, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Stanford, California

  • Site not named

    Tarzana, California

  • Site not named

    Torrance, California

  • Site not named

    Denver, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    Glenwood Springs, Colorado

  • Site not named

    Grand Junction, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Aventura, Florida

  • Site not named

    Boca Raton, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Decatur, Illinois

Showing 40 of 379 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.